We are so excited to see all our friends and collegues next week at SupplySide West. 📍 Visit us at Booth #1631 to learn about the benefits of effera™, the first human equivalent lactoferrin. 🔬Discover insights from effera’s™ latest clinical study. 💰Learn about Helaina's $45 million Series B funding to accelerate our commercialization efforts of effera™. 😋Come by the booth for exclusive samples of effera™ and experience its benefits firsthand. 🗓️Don’t miss out—use the link below to book an appointment with our team, or simply stop by Booth #1631 for a chat. https://lnkd.in/dNZEXNpm
Helaina’s Post
More Relevant Posts
-
Do you work in #clinicaltrials? Ever face a problem and wish you had "phone-a-friend' capability? You do! Feel free to ask Michael Tanen and me for help on any #biomarker & #biospecimen operations related topics via #ClinEco. Registration is easy and free. The Doctor will see you now 😊 #precisionMedicine #unicorns #biomarkers #biospecimen
Navigating the complexities of laboratory and biomarker services requires expert insight. From biospecimen handling to cutting-edge biomarker discovery, our Luminaries are equipped to help you enhance your trial’s precision and outcomes through smart lab service strategies. Brenda Yanak, Michael Tanen #Biomarkers #BiospecimenHandling #ClinicalInnovation *Only registered members can ask questions. Not registered yet? Join the ClinEco community today - it's free and simple.
-
Developing a new drug takes long-term commitment but the reward can be life-changing. Watch this video as Race Oncology CEO speaks with HotCopper to break down the drug development process and biotech companies' appeal to the investors. #oncologydrugs #biotech #investment
We were lucky to have been invited to participate in a HotCopper webinar last week which delved into the topic of “Demystifying clinical trials and approval processes for ASX-listed companies”. Race Oncology CEO Dr Daniel Tillett joined Hot Copper's Sonia Madigan to discuss Race's journey through the drug development process with our drug #bisantrene and why #biotech investments can pay dividends for patient investors. Watch the interview here: https://lnkd.in/g93jQK3f #BiotechInvestment #CancerTreatment #cardioprotection
Race CEO Daniel Tillett Joins Hot Copper webinar to discuss bringing medical developments to market
https://www.youtube.com/
-
We are pleased to share the second session of our brand-new Fireside series in partnership with FLUIDDA. During this session, experts—Dr. Will Ganley and Dr. Eleanor Canipa from Nanopharm, alongside Dr. Jan De Backer from Fluidda will dive deeper into FDA Product Guidances. They explore two key insights: how in-silico models can serve as digital equivalents to clinical trials, and why (charcoal) PK studies in healthy volunteers may not accurately reflect PK in the target patient population. Watch the video to learn more, and if you have any questions, do come and meet us in person at DDL next month! #NanopharmInnovates #FDAUpdates #PharmaceuticalInnovation #SmartTrack #OINDP #MedicalDevice
-
We are back with 'Lessons from the SV95C qualification Series'. In 2023, Sysnav and its partners qualified SV95C, the first digital primary endpoint to the European Medicines Agency (EMA). In the next few months, we'll share our biggest takeaways from the qualification. 🤝 Lesson 2: It takes a village Creating meaningful endpoints requires interaction between physicians, engineers, patient associations, and regulators. Digital endpoints should be: 👉 Meaningful for patients 👉 Used by clinicians 👉 Trusted by regulators The SV95C EMA qualification is the result of collaboration with University of Oxford, Roche, Parent Project Muscular Dystrophy, Muscular Dystrophy UK, World Duchenne Organization, and many others.
-
-
If you attended #DIA2024 and find yourself in a post-conference slump, I've got exciting news for you! Among the sponsors at DIA, more than 30 companies have announced plans to start phase 2 or phase 3 trials since last month. For instance, Tyra Bio, a company with just over 50 employees, is gearing up for a Phase 2 study in pediatric achondroplasia. They've already secured significant funding in 2024. Don't let important opportunities slip through the cracks after conferences! Connect with me at [email protected] or DM me to discuss how we can help you achieve your conference ROI and make your sales teams more proactive. #conferences #sponsors #clinicaltrials
-
If you're wondering how your IDS (or similar clinical space) operations/workflows could be streamlined (especially if you're paper based), take a look at our latest case study. #ids #clinicalresearch #researchpharmacy
Discover how a leading research institution in the Midwest achieved an 83% reduction in documentation time by implementing Vestigo®. Our latest case study reveals the transformative impact of automation on clinical trial management. Key insights include: - Reducing task durations from 30 minutes to less than five - Eliminating physical documents, freeing up critical storage space Download the case study today to learn how Vestigo® can transform your clinical trial operations and drive your institution's success: https://hubs.ly/Q02Lv_-00
-
-
Next week I’ll be joining the Ori team at #CGMesa24 in Arizona. Two things you should not miss: 1️⃣ Panel Discussion on Mon, 7th at 7:45 AM: Gain insights into pre-clinical development strategies to help safeguard commercial success. 💡 2️⃣ IRO Platform Demo: See our cutting-edge IRO technology in action. Be sure to book your demo slot before they fill up! 🤖 Please come say hello and let's chat about driving innovation forward, together! #manufacturingbrighterfutures
Heading to Meeting on the Mesa next week? Here's where you can find the Ori team ⬇️ 🧬 Monday October 7 | 7:45 AM – Jason C. Foster, CEO of Ori Biotech, will be chairing a workshop "What can be done during pre-clinical development to avoid commercial failure?" He’ll be joined by: Julie G. Allickson, PhD, Mayo Clinic Bruce Thompson, Kincell Bio Matthew Hewitt, Charles River Laboratories Andrew Snowden, Johnson & Johnson 🤝 Meet the Ori Team – Thomas Heathman, Lee H. Unroe, Kale Feeter, Sarah Haecker Meeks, PhD, Marianna Mavropoulou, Kara Win, Niamh O'Connell, William Raimes will all be attending this year's conference, and are looking forward to connecting with colleagues to discuss the latest advances in CGT manufacturing. Connect with them to arrange a meeting or schedule an IRO demo! 🔍 Live IRO Demos – Visit the 'Camelback' room on the 2nd floor of the Frank Lloyd Wright building for hands-on demos of how IRO® is accelerating product development and Automating Better Biology. Sign up for your hands-on IRO demo ➡️ https://lnkd.in/eZ8sUC4x #ManufacturingBrighterFutures #CellTherapy #GeneTherapy #PatientAccess #Biotechnology
-
-
Following the 2 year anniversary of the signing of the #InflationReductionAct our experts Stephen Williams & Kim Vukhac Glasser take a closer look at the IRA’s potential impact on clinical trials. Request a copy of our latest whitepaper here: mrwd.co/CRO_outlook
CRO Outlook: On Trials
https://www.marwoodgroup.com
-
Register for this webinar to learn how configurable solutions are transforming study launches by reducing coding errors, enhancing consistency across studies and enabling the acquisition of more reliable data. This not only streamlines the process but also makes it more cost-effective compared to traditional customized solutions that require complex and lengthy implementations.
Is your clinical trial platform built to deliver the future of clinical research? Join our Xtalks webinar on May 30th with YPrime's Chase Carmeans and Ryan Ridge and learn how to optimize #eCOA and #IRT to deliver a modern clinical trial. Register here: https://lnkd.in/d7UvZDKr.
-
